Logo image of TLIS

TALIS BIOMEDICAL CORP (TLIS) Stock Price, Quote, News and Overview

NASDAQ:TLIS - Nasdaq - US87424L2079 - Common Stock - Currency: USD

4.38  +0.22 (+5.29%)

After market: 4.49 +0.11 (+2.51%)

TLIS Quote, Performance and Key Statistics

TALIS BIOMEDICAL CORP

NASDAQ:TLIS (8/30/2024, 8:26:04 PM)

After market: 4.49 +0.11 (+2.51%)

4.38

+0.22 (+5.29%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
Statistics
52 Week High9.6
52 Week Low3.42
Market Cap7.97M
Shares1.82M
Float1.67M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)11-12 2024-11-12/amc
IPO02-12 2021-02-12


TLIS short term performance overview.The bars show the price performance of TLIS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30 -40 -50

TLIS long term performance overview.The bars show the price performance of TLIS in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of TLIS is 4.38 USD. In the past month the price decreased by -50.79%. In the past year, price decreased by -27.24%.

TALIS BIOMEDICAL CORP / TLIS Daily stock chart

TLIS Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 28.89 234.01B
ISRG INTUITIVE SURGICAL INC 80.74 211.07B
BSX BOSTON SCIENTIFIC CORP 41.63 154.00B
SYK STRYKER CORP 31.4 145.92B
MDT MEDTRONIC PLC 16.84 115.33B
BDX BECTON DICKINSON AND CO 16.35 65.30B
EW EDWARDS LIFESCIENCES CORP 27.98 43.23B
GEHC GE HEALTHCARE TECHNOLOGY 20.29 41.62B
IDXX IDEXX LABORATORIES INC 40.25 37.07B
DXCM DEXCOM INC 53.81 34.68B
RMD RESMED INC 26.21 34.03B
PHG KONINKLIJKE PHILIPS NVR- NY 17.5 24.02B

About TLIS

Company Profile

TLIS logo image Talis Biomedical Corp. develops and commercializes innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company is headquartered in Chicago, Illinois and currently employs 99 full-time employees. The company went IPO on 2021-02-12. The firm is focused on advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care.

Company Info

TALIS BIOMEDICAL CORP

1375 West Fulton Market, Suite 700

Chicago ILLINOIS 94025 US

CEO: Brian Coe

Employees: 99

Company Website: https://talisbio.com/

Phone: 16504333000

TALIS BIOMEDICAL CORP / TLIS FAQ

What is the stock price of TALIS BIOMEDICAL CORP today?

The current stock price of TLIS is 4.38 USD. The price increased by 5.29% in the last trading session.


What is the ticker symbol for TALIS BIOMEDICAL CORP stock?

The exchange symbol of TALIS BIOMEDICAL CORP is TLIS and it is listed on the Nasdaq exchange.


On which exchange is TLIS stock listed?

TLIS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for TALIS BIOMEDICAL CORP stock?

6 analysts have analysed TLIS and the average price target is 5.1 USD. This implies a price increase of 16.44% is expected in the next year compared to the current price of 4.38. Check the TALIS BIOMEDICAL CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is TALIS BIOMEDICAL CORP worth?

TALIS BIOMEDICAL CORP (TLIS) has a market capitalization of 7.97M USD. This makes TLIS a Nano Cap stock.


How many employees does TALIS BIOMEDICAL CORP have?

TALIS BIOMEDICAL CORP (TLIS) currently has 99 employees.


What are the support and resistance levels for TALIS BIOMEDICAL CORP (TLIS) stock?

TALIS BIOMEDICAL CORP (TLIS) has a resistance level at 4.52. Check the full technical report for a detailed analysis of TLIS support and resistance levels.


Is TALIS BIOMEDICAL CORP (TLIS) expected to grow?

The Revenue of TALIS BIOMEDICAL CORP (TLIS) is expected to decline by -100% in the next year. Check the estimates tab for more information on the TLIS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy TALIS BIOMEDICAL CORP (TLIS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does TALIS BIOMEDICAL CORP (TLIS) stock pay dividends?

TLIS does not pay a dividend.


When does TALIS BIOMEDICAL CORP (TLIS) report earnings?

TALIS BIOMEDICAL CORP (TLIS) will report earnings on 2024-11-12, after the market close.


What is the Price/Earnings (PE) ratio of TALIS BIOMEDICAL CORP (TLIS)?

TALIS BIOMEDICAL CORP (TLIS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-31.43).


What is the Short Interest ratio of TALIS BIOMEDICAL CORP (TLIS) stock?

The outstanding short interest for TALIS BIOMEDICAL CORP (TLIS) is 0.34% of its float. Check the ownership tab for more information on the TLIS short interest.


TLIS Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

TLIS Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to TLIS. While TLIS has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TLIS Financial Highlights

Over the last trailing twelve months TLIS reported a non-GAAP Earnings per Share(EPS) of -31.43. The EPS increased by 42.72% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -69.35%
ROE -100.93%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%28.28%
Sales Q2Q%-93.25%
EPS 1Y (TTM)42.72%
Revenue 1Y (TTM)-65.21%

TLIS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 37% to TLIS. The Buy consensus is the average rating of analysts ratings from 6 analysts.

For the next year, analysts expect an EPS growth of 27.62% and a revenue growth -100% for TLIS


Ownership
Inst Owners21.86%
Ins Owners18.29%
Short Float %0.34%
Short Ratio0.24
Analysts
Analysts36.67
Price Target5.1 (16.44%)
EPS Next Y27.62%
Revenue Next Year-100%